SCHEMBL6890800

SCHEMBL6890800

CC(C)(C)OC(=O)N1Cc2cn[nH]c2C1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.62
NAMPT P43490 1/20 0.59
MAPK1 P28482 1/20 0.45
ESR2 Q92731 1/20 0.43
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
HDAC1 Q13547 1/20 0.41
DDB1 Q16531 3/20 0.40
CRBN Q96SW2 3/20 0.40
MAPT P10636 1/20 0.40
ACACB O00763 5/20 0.39
PDK2 Q15119 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrazole SCHEMBL4014508 0.90 NR1H2 (0.56) NR1H2NAMPTMAPK1ESR2PSEN1
SCHEMBL8223979 0.87 NR1H2 (0.55) NR1H2NAMPTMAPK1ESR2PSEN1
SCHEMBL1018783 0.87 NR1H2 (0.58) NR1H2NAMPTMAPK1ESR2PSEN1
SCHEMBL30793545 0.85 NR1H2 (0.56) NR1H2NAMPTMAPK1ESR2PSEN1
SCHEMBL20557473 0.82 NR1H2 (0.49) NR1H2NAMPTMAPK1PSEN1PSEN2
SCHEMBL13081375 0.81 NR1H2 (0.57) NR1H2NAMPTMAPK1ESR2PSEN1
SCHEMBL31535874 0.80 NR1H2 (0.53) NR1H2NAMPTMAPK1ESR2MAPT
SCHEMBL31549281 0.79 NR1H2 (0.55) NR1H2NAMPTMAPK1ESR2MAPT
SCHEMBL28970122 0.78 NR1H2 (0.48) NR1H2NAMPTMAPK1PSEN1PSEN2
SCHEMBL34469116 0.78 NR1H2 (0.48) NR1H2NAMPTMAPK1PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713319-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF Insilico Medicine IP Limited (HK) 2026-03-25 EP disclosed
EP-3623372-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH INC (US) 2026-02-04 EP disclosed
US-12398139-B2 Modulators of AMPA receptor signaling CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) 2025-08-26 US disclosed
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 EP disclosed
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-17 US disclosed
EP-4573089-A2 KRAS INHIBITORS Bristol-Myers Squibb Company (US) 2025-06-25 EP disclosed
CN-119998275-A KRAS inhibitors 百时美施贵宝公司 2025-05-13 CN disclosed
EP-3935059-B1 MODULATORS OF AMPA RECEPTOR SIGNALING CAMH (CA) 2025-04-23 EP disclosed
WO-2025068990-A1 SELECTIVE AMPA RECEPTOR MODULATORS CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) 2025-04-03 WO disclosed
CN-113557017-B Inhibitors of cyclin-dependent kinase 7 and uses thereof 丹娜-法伯癌症研究院 2024-11-29 CN disclosed
US-8415297-B2 Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME CORP. (US) 2013-04-09 US disclosed
WO-2013003250-A1 PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-01-03 WO disclosed
WO-2013003249-A1 NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR MERCK SHARP & DOHME CORP. (US) 2013-01-03 WO disclosed
US-20120149637-A1 AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK SHARP & DOHME LLC 2012-06-14 US disclosed
US-20120149734-A1 AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK SHARP & DOHME LLC 2012-06-14 US disclosed
US-20120149637-A1 AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK SHARP & DOHME LLC 2012-06-14 US disclosed
US-20120149734-A1 AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK SHARP & DOHME LLC 2012-06-14 US disclosed
WO-2011146358-A1 SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES MERCK SHARP & DOHME CORP. (US) 2011-11-24 WO disclosed
WO-2011028455-A1 AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK SHARP & DOHME CORP. (US) 2011-03-10 WO disclosed
WO-2010056708-A1 AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK SHARP & DOHME CORP. (US) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149734-A1 AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES DPP4, DPP3, DPP7 NR1H2 3087/4885NAMPT 801/4885MAPK1 3960/4885
US-12398139-B2 Modulators of AMPA receptor signaling GRM2, GRM1, GRIK1 NR1H2 108/4885NAMPT 2410/4885MAPK1 219/4885
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NQO1, VHL, SDHA NR1H2 1173/4885NAMPT 147/4885MAPK1 3535/4885
US-20120149637-A1 AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES DPP4, DPP3, DPP7 NR1H2 3087/4885NAMPT 801/4885MAPK1 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.